Related Experiment Videos
Glucose counterregulation in pre-school-age diabetic children with recurrent hypoglycemia during conventional
Insights
Defective glucagon response contributes to severe hypoglycemia in young diabetic children on conventional therapy. Continuous subcutaneous insulin infusion (CSII) significantly reduces these dangerous low blood glucose events.
Area of Science:
- Pediatric Endocrinology
- Metabolic Disorders
- Diabetes Mellitus Research
Background:
- Severe hypoglycemia is a significant complication in pre-school-aged children with diabetes mellitus.
- Conventional therapy (CT) in some diabetic children leads to frequent and severe hypoglycemic episodes.
- Understanding the counterregulatory mechanisms is crucial for managing hypoglycemia in pediatric diabetes.
Purpose of the Study:
- To investigate the role of immature or defective glucose counterregulation in severe hypoglycemia experienced by young diabetic children.
- To assess metabolic and hormonal responses to insulin infusion in this patient group.
- To evaluate the efficacy of continuous subcutaneous insulin infusion (CSII) in reducing hypoglycemia.
Main Methods:
- Six pre-school-aged diabetic children with severe hypoglycemia underwent an insulin infusion test (40 mU/kg i.v. for 60 min).
- Metabolic parameters (blood glucose, 3-hydroxybutyrate) and hormonal responses (epinephrine, norepinephrine, growth hormone, glucagon) were measured.
- Patients were subsequently treated with continuous subcutaneous insulin infusion (CSII), and hypoglycemia frequency was compared.
Main Results:
- Hormonal counterregulatory responses (epinephrine, norepinephrine, growth hormone) were normal for the age group.
- Glucagon response to insulin infusion was deficient, similar to observations in diabetic adults.
- Continuous subcutaneous insulin infusion (CSII) led to a 20-fold decrease in severe hypoglycemic reactions.
- A significant inverse correlation was found between hypoglycemia frequency and blood glucose nadir during the insulin infusion test (r = .94, P < .001).
Conclusions:
- Deficient glucagon response, rather than other counterregulatory hormones, may predispose young diabetic children to severe hypoglycemia.
- Continuous subcutaneous insulin infusion (CSII) is an effective therapy for significantly reducing severe hypoglycemia in this vulnerable pediatric population.
- The insulin infusion test can predict the risk of severe hypoglycemia and the potential benefit of CSII therapy.
Abstract:
To determine whether immature or defective glucose counterregulation was responsible for the severe recurrent hypoglycemic episodes (3.6 per patient per year) observed during conventional therapy (CT) in six pre-school-age diabetic children, we investigated their metabolic and hormonal responses to insulin infusion (40 mU/kg i.v. for 60 min). Counterregulation was considered adequate because no patient experienced symptoms requiring discontinuation of the test, and blood glucose (BG) nadirs averaged 42 +/- 5 mg/dl. Glucose production rate decreased from 4.2 +/- 0.2 to 2.6 +/- 0.6 mg X kg-1 X min-1. Blood 3-hydroxybutyrate levels were elevated (approximately 3 mM) and did not change during insulin infusion. The responses of epinephrine (from 137 +/- 37 to 393 +/- 143 pg/ml), norepinephrine (from 145 +/- 33 to 347 +/- 152 pg/ml), and growth hormone (from 6.0 +/- 1.5 to 20.3 +/- 5.1 ng/ml) were normal for this age group. As previously observed in diabetic adults, glucagon response was deficient (from 117 +/- 30 to 114 +/- 18 pg/ml). The six children were subsequently treated with continuous subcutaneous insulin infusion (CSII), which resulted in a 20-fold decrease in the number of severe hypoglycemic reactions. Predisposition to severe hypoglycemia in this subset of diabetic children, which remains a refractory problem even after considerable efforts have been made to decrease them, may thus be sharply decreased with CSII therapy. During this therapy, a significant inverse correlation appeared between the individual frequency of BG values less than 40 mg/dl and BG nadir during the insulin infusion test (r = .94, P less than .001).